The application and outcome of standard of care treatment in elderly women with ovarian cancer: A literature review over the last 10 years

Frontiers in Oncology

Volumn 6, Issue MAR, 2016, Pages

  Gibson, Steven J ^a   Fleming, Gini F ^b   Temkin, Sarah M ^c   Chase, Dana M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Care; Chemotherapy; Elderly; Outcomes; Ovarian cancer; Treatment

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; PLATINUM;

ABDOMINAL SURGERY; ACTIVITY OF DAILY LIVING ASSESSMENT; CANCER CHEMOTHERAPY; DEPRESSION ANXIETY STRESS SCALE; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; REVIEW; THERMOTHERAPY;

EID: 84964555262     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00063     Document Type: Review

References (60)

1. Bureau USC. Table 3: Projections of the Population by Sex and Selected Age Groups for the United States: 2015 to 2060 (2014). Available from: http://www.census.gov/population/projections/data/national/2014/summarytables.html
2. Tew WP, Fleming GF. Treatment of ovarian cancer in the older woman. Gynecol Oncol (2015) 136(1):136-42. doi: 10.1016/j.ygyno.2014.10.028
3. Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol (2012) 51(4):441-53. doi:10.3109/0284186X.2011.653437
4. NCI. SEER Stat Fact Sheets: Ovary Cancer. Surveillance, Epidemiology, and End Results Program, 1975-2012. Available from: http://seer.cancer.gov/statfacts/html/ovary.html
5. Balducci L. Management of cancer in the elderly. Oncology (2006) 20(2):135-43
6. Freyer G, Tew WP, Moore KN. Treatment and trials: ovarian cancer in older women. Am Soc Clin Oncol Educ Book (2013):227-35. doi:10.1200/EdBook_AM.2013.33.227
7. Wright JD, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer (2014) 120(8):1246-54. doi:10.1002/cncr.28508
8. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol (2007) 18(7):1253-9. doi:10.1093/annonc/mdm126
9. Poynter JN, Inoue-Choi M, Ross JA, Jacobs DR Jr, Robien K. Reproductive, lifestyle, and anthropometric risk factors for cancer in elderly women. Cancer Epidemiol Biomarkers Prev (2013) 22(4):681-7. doi:10.1158/1055-9965.EPI-12-0966
10. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer (2006) 95(10):1314-20. doi:10.1038/sj.bjc.6603457
11. Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, et al. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res (2007) 27(1B):611-7
12. Janda M, Youlden DR, Baade PD, Jackson D, Obermair A. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer (2008) 18(5):896-907. doi:10.1111/j.1525-1438.2007.01122.x
13. Giuliani J, Drudi F. Ovarian cancer in elderly patients: a difference in treatment based on age? Arch Gynecol Obstet (2012) 286(6):1545-8. doi:10.1007/s00404-012-2486-0
14. Hilpert F, du Bois A, Greimel ER, Hedderich J, Krause G, VenhoffL, et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged= 70 years with advanced ovarian cancer-a study by the AGO OVAR Germany. Ann Oncol (2007) 18(2):282-7. doi:10.1093/annonc/mdl401
15. Ben-Ami I, Vaknin Z, Schneider D, Halperin R. Perioperative morbidity and mortality of gynecological oncologic surgery in elderly women. Int J Gynecol Cancer (2006) 16(1):452-7. doi:10.1111/j.1525-1438.2006.00478.x
16. Susini T, Amunni G, Busi E, Villanucci A, Carriero C, Taddei G, et al. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer (2007) 17(3):581-8. doi:10.1111/j.1525-1438.2007.00836.x
17. Cascales-Campos P, Gil J, Gil E, Feliciangeli E, López V, Gonzalez AG, et al. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients. Eur J Obstet Gynecol Reprod Biol (2014) 179:88-93. doi:10.1016/j.ejogrb.2014.05.018
18. Sabatier R, Calderon B Jr, Lambaudie E, Chereau E, Provansal M, Cappiello MA, et al. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. Int J Gynecol Cancer (2015) 25(5):815-22. doi:10.1097/IGC.0000000000000418
19. Chia VM, O'Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol (2013) 129(2):346-52. doi:10.1016/j.ygyno.2013.02.014
20. Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol (2013) 24(11):2808-13. doi:10.1093/annonc/mdt360
21. GoffBA, Matthews BJ, Larson EH, Andrilla CH, Wynn M, Lishner DM, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer (2007) 109(10):2031-42. doi:10.1002/cncr.22604
22. van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol (2012) 125(3):649-54. doi:10.1016/j.ygyno.2012.02.033
23. Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. Ovarian cancer in the elderly: impact of surgery on morbidity and survival. Eur J Surg Oncol (2011) 37(6):537-42. doi:10.1016/j.ejso.2011.03.136
24. Jørgensen TL, Teiblum S, Paludan M, Poulsen LØ, Jørgensen AY, Bruun KH, et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol (2012) 127(2):367-74. doi:10.1016/j.ygyno.2012.07.001
25. O'Malley CD, Shema SJ, Cress RD, Bauer K, Kahn AR, Schymura MJ, et al. The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a centers for disease control and prevention study. J Womens Health (2012) 21(9):887-94. doi:10.1089/jwh.2012.3781
26. Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, et al. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. J Ovarian Res (2013) 6(1):42. doi:10.1186/1757-2215-6-42
27. Uyar D, Frasure HE, Markman M, von Gruenigen VE, et al. Treatment patterns by decade of life in elderly women (= 70 years of age) with ovarian cancer. Gynecol Oncol (2005) 98(3):403-8. doi:10.1016/j.ygyno.2005.04.037
28. Díaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Gordon TA, Armstrong DK, et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol (2005) 99(2):352-7. doi:10.1016/j.ygyno.2005.06.005
29. McLean KA, Shah CA, Thompson SA, Gray HJ, Swensen RE, GoffBA. Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol (2010) 118(1):43-6. doi:10.1016/j.ygyno.2010.03.002
30. Gardner GJ. Ovarian cancer cytoreductive surgery in the elderly. Curr Treat Options Oncol (2009) 10(3-4):171-9. doi:10.1007/s11864-009-0114-4
31. Alphs HH, Zahurak ML, Bristow RE, Díaz-Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol (2006) 103(3):1048-53. doi:10.1016/j.ygyno.2006.06.019
32. Perri T, Katz T, Korach J, Beiner ME, Jakobson-Setton A, Ben-Baruch G. Treating gynecologic malignancies in elderly patients. Am J Clin Oncol (2015) 38(3):278-82. doi:10.1097/COC.0b013e318297d464
33. Fanfani F, Fagotti A, Salerno MG, Margariti PA, Gagliardi ML, Gallotta V, et al. Elderly and very elderly advanced ovarian cancer patients: does the age influence the surgical management? Eur J Surg Oncol (2012) 38(12):1204-10. doi:10.1016/j.ejso.2012.08.003
34. Fotopoulou C, Savvatis K, Steinhagen-Thiessen E, Bahra M, Lichtenegger W, Sehouli J. Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival. Int J Gynecol Cancer (2010) 20(1):34-40. doi:10.1111/IGC.0b013e3181c10c04
35. Lim MC, Kang S, Song YJ, Park SH, Park SY. Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer. J Korean Med Sci (2010) 25(7):1034-40. doi:10.3346/jkms.2010.25.7.1034
36. Sharma S, Driscoll D, Odunsi K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol (2005) 193(6):2077-82. doi:10.1016/j.ajog.2005.06.074
37. Langstraat C, Aletti G, Cliby W. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol (2011) 123(2):187-91. doi:10.1016/j.ygyno.2011.06.031
38. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol (2011) 120(1):23-8. doi:10.1016/j.ygyno.2010.09.010
39. Earle CC, Schrag D, Neville BA, YabroffKR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 98(3):172-80. doi:10.1093/jnci/djj019
40. Mahdi H, Wiechert A, Lockhart D, Rose PG. Impact of age on 30-day mortality and morbidity in patients undergoing surgery for ovarian cancer. Int J Gynecol Cancer (2015) 25(7):1216-23. doi:10.1097/IGC.0000000000000486
41. Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol (2008) 110(2):133-9. doi:10.1016/j.ygyno.2008.03.008
42. Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Neugut AI, et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol (2011) 123(3):467-73. doi:10.1016/j.ygyno.2011.08.027
43. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol (2006) 100(2):300-7. doi:10.1016/j.ygyno.2005.08.029
44. Cloven NG, Manetta A, Berman ML, Kohler MF, DiSaia PJ. Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol (1999) 73(1):137-9. doi:10.1006/gyno.1998.5337
45. Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol (2013) 107(2):195-200. doi:10.1002/jso.23171
46. Thrall MM, GoffBA, Symons RG, Flum DR, Gray HJ. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol (2011) 118(3):537. doi:10.1097/AOG.0b013e31822a6d56
47. Wright J, Doan T, McBride R, Jacobson J, Hershman D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer (2008) 98(7):1197-203. doi:10.1038/sj.bjc.6604298
48. Trédan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol (2007) 18(2):256-62. doi:10.1093/annonc/mdl400
49. Kothari R, Nagel C, Koopmeiners JS, Ivy JJ, Geller M, Salani R, et al. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol (2010) 119(3):491-5. doi:10.1016/j.ygyno.2010.08.026
50. Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol (2007) 106(2):381-7. doi:10.1016/j.ygyno.2007.04.012
51. Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol (2008) 109(1):33-8. doi:10.1016/j.ygyno.2008.01.001
52. Moore KN, Frank SG, Alward EK, Landrum LM, Myers TK, Walker JL, et al. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients. Cancer (2009) 115(7):1472-80. doi:10.1002/cncr.24190
53. Shirai T, Imanaka Y, Sekimoto M, Ishizaki T; QIP Ovarian Cancer Expert Group. Primary chemotherapy patterns for ovarian cancer treatment in Japan. J Obstet Gynaecol Res (2009) 35(5):926-34. doi:10.1111/j.1447-0756.2009.01033.x
54. Nurgalieva Z, Liu CC, Du XL. Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer. Int J Gynecol Cancer (2009) 19(8):1314-21. doi:10.1111/IGC.0b013e3181b7662d
55. Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther (2010) 17(2):148-58. doi:10.1097/MJT.0b013e3181a3e50b
56. Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D Jr, et al. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol (2015) 137(3):401-5. doi:10.1016/j.ygyno.2015.03.052
57. Delotte J, Arias T, Guerin O, Boulahssass R, Bereder I, Bongain A, et al. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women. Acta Obstet Gynecol Scand (2015) 94(4):435-9. doi:10.1111/aogs.12577
58. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, et al. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol (2011) 22(11):2417-23. doi:10.1093/annonc/mdr001
59. Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol (2009) 71(3):233-41. doi:10.1016/j.critrevonc.2008.12.010
60. Mooney SJ, Winner M, Hershman DL, Wright JD, Feingold DL, Allendorf JD, et al. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol (2013) 129(1):107-12. doi:10.1016/j.ygyno.2012.12.028